Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.045
Sell
RSI(14)
34.637
Neutral
STOCH(KDJ)(9,3,3)
39.913
Buy
ATR(14)
0.128
Low Volatility
CCI(14)
-67.234
Neutral
Williams %R
72.157
Sell
TRIX(12,20)
-1.435
Sell
StochRSI(14)
100.000
Overbought
Search
Beyondspring Inc
BYSIAdd to Watchlist
1.170USD
-0.015-1.27%
Close 07-28 16:00（ET）Quotes delayed by 15 min
48.11MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-1.27%
5 Days
-6.40%
1 Month
-30.77%
6 Months
-24.52%
Year to Date
-28.22%
1 Year
-39.06%
Key Figures
1.190Open
1.210High
6.62KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
0.02%Turnover Ratio
1.185Prev. Close
1.130Low
4.57KTurnover
LossP/E Static
-1.40P/B
0.00%Div Yield TTM
-30.56%ROA
3.44052wk High
0.22Volume Ratio
-11.12MNet Profit
41.12MShares
-0.1885EPS TTM
0.43Beta
-321.46%ROE
1.17552wk Low
6.74%Amplitude
100.00%Gross Margin
48.11MMarket Cap
-5.63Reward/Risk
5.73%Risk Rate
TradingKey Stock Score of Beyondspring Inc
Currency: USD Updated: 2026-07-28Key Insights
Beyondspring Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 185 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beyondspring Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Beyondspring Inc Highlights
StrengthsRisks
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Fairly Valued
The company’s latest PE is -6.29, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.01M shares, decreasing 5.93% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 10.64K shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Beyondspring Inc News
More news coming soon, stay tuned...
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.137
Buy
MA10
1.201
Sell
MA20
1.410
Sell
MA50
1.533
Sell
MA100
1.573
Sell
MA200
1.665
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Beyondspring Inc Info
BeyondSpring Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. It also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Ticker SymbolBYSI
CompanyBeyondspring Inc
CEOHuang (Lan)
Websitehttps://www.beyondspringpharma.com/en/
Shareholders
Related Instruments
-0.75%
-0.41%
+0.49%
+0.16%
-1.07%
-0.64%
-1.34%
+1.26%
-1.15%
-0.30%
-0.72%
-1.36%
-0.03%
-0.94%
-1.44%
0.00%
+0.24%
+1.34%
+1.29%
-1.45%Popular Instruments
FAQs
What is the current price of Beyondspring Inc (BYSI)?
The current price of Beyondspring Inc (BYSI) is 1.17.
What is the symbol of Beyondspring Inc?
The ticker symbol of Beyondspring Inc is BYSI.
What is the 52-week high of Beyondspring Inc?
The 52-week high of Beyondspring Inc is 3.44.
What is the 52-week low of Beyondspring Inc?
The 52-week low of Beyondspring Inc is 1.18.
What is the market capitalization of Beyondspring Inc?
The market capitalization of Beyondspring Inc is 48.73M.
What is the Earnings Per Share (EPS TTM) of Beyondspring Inc (BYSI)?
The Earnings Per Share (EPS TTM) of Beyondspring Inc (BYSI) is -0.02.